logo
Indian-origin pharma tycoon arrested in US for healthcare fraud

Indian-origin pharma tycoon arrested in US for healthcare fraud

India Today3 days ago

A US-based, Indian-origin pharma tycoon was arrested at Los Angeles International Airport over his involvement in a $149-million healthcare fraud. Tonmoy Sharma, 61, is the founder and former CEO of Sovereign Health Group — an addiction treatment provider — and is originally from Guwahati, Assam.Sharma, who studied medicine at Dibrugarh Medical College and interned at the Safdarjung Hospital in Delhi, was arrested on May 29 on an eight-count federal grand jury indictment alleging he submitted more than $149 million in fraudulent claims to health insurers. As per US Attorney's Office, Central District of California, Sovereign Health Group fraudulently enrolled patients into insurance plans without their knowledge, using deceptive tactics.advertisementSharma's company billed insurers for unauthorised urinalysis tests, generating over $29 million in fraudulent claims.
In addition, Sharma paid more than $21 million in illegal kickbacks for patient referrals, according to a release from the US Justice Department.Co-defendant in the case, Paul Jin Sen Khor, was also arrested and pleaded not guilty. His trial is set for July 29.Sharma has been charged with four counts of wire fraud, one count of conspiracy, and three counts of illegal remunerations for referrals to clinical treatment facilities, according to the US Attorney's Office of the Central District of California.The investigation into Tonmoy Sharma's now-defunct Sovereign Health Group, which ran multiple addiction treatment centres in Southern California, was on since June 2017, according to a report by NBC Los Angeles.The FBI raided its treatment facilities, its San Clemente headquarters and Sharma's residence in San Juan Capistrano, according to the report.advertisementThe Sovereign Health Group shut down in 2018.WHO IS TONMOY SHARMAA pioneer in schizophrenia research and treatment, Tonmoy Sharma, is an internationally recognised research psychiatrist. His work focussed on brain function, cognition, and human behaviour in mental illnesses. He is the eldest son of the late Phani Sharma, a renowned theatre actor, playwright, film actor, and director, who also owned Anuradha Cinema.Coming from a culturally rich and affluent background, Sharma established his career in the US after earning his MBBS from Dibrugarh University, Assam, in 1987. He obtained his first medical licence from the Indian Medical Council in 1987, followed by a second from the General Medical Council of the United Kingdom in 1988.Throughout his career, Sharma made significant contributions to psychiatric research. He has peer-reviewed for 15 international medical journals, served on multiple editorial boards, and participated in several advisory groups on antipsychotic medication. He has directed over 20 clinical investigations, authored more than 200 peer-reviewed journal articles, and co-authored five books on schizophrenia.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

What is RSV and why are infants especially at risk in India?
What is RSV and why are infants especially at risk in India?

Time of India

time10 minutes ago

  • Time of India

What is RSV and why are infants especially at risk in India?

Respiratory Syncytial Virus, commonly known as RSV, is the leading cause of respiratory illness in children and infants worldwide. In India, RSV has also become a major issue for parents as well as pediatricians, particularly in the post-monsoon and winter seasons when cases surge. Although the nation continues to establish complete surveillance information, existing studies in tertiary care facilities show that RSV contributes 30% to 50% of bronchiolitis and pneumonia incidents in children aged two years and below. RSV is usually responsible for the symptoms of a cold in older children and adults. Nevertheless, in infants—especially those under six months of age, those who were premature at birth, or those with underlying health issues—the virus may cause severe lower respiratory tract infections, including bronchiolitis (inflammation of small airways) and pneumonia. These two diseases usually require hospitalization, and hospitalization rates between 3 and 5 per 100 infants less than one year of age per year have been estimated in India. The risks are not equal throughout the nation. Geographic and socioeconomic variations account for both the risk of and outcome of RSV infection. Children living in lower-income populations or in densely populated urban environments can have increased exposure from lesser access to healthcare, suboptimal ventilation, and slower diagnosis. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Eat 1 Teaspoon Every Night, See What Happens A Week Later [Video] getfittoday Undo Seeing the international burden of RSV, the World Health Organization (WHO) recently supported maternal RSV vaccination as a prevention approach. This entails immunizing pregnant women so that antibodies are passed on to the unborn child, providing immunity in the vulnerable early months of life. Although not yet included in India's Universal Immunization Programme (UIP), Indian health authorities, such as the Indian Academy of Pediatrics, are in the process of evaluating the vaccine's safety, effectiveness, and affordability in India. Phased introduction in high-risk groups could be the initial step. Apart from vaccines, monoclonal antibodies too have been promising in the prevention of RSV-related complications. These provide passive immunity in a single dose of injection. But the big constraint is cost. Without government incentives or being covered under public health schemes, these therapies could prove to be out of reach for the majority of Indian families. Differential pricing models and collaborations with insurance companies will become paramount in order to expand access. More encouragingly, Indian drug makers are not idle either. Bharat Biotech and Serum Institute of India have initiated RSV research programs and are likely to bank on their experience in the production of pediatric and maternal vaccines. Tie-ups with global firms can also open the way for local production of monoclonal antibodies, leading to costs savings as well as wider availability. Experts put wide availability of RSV vaccines and antibodies in India at least 2 to 4 years down the road. Early access could start in corporate or private hospitals dealing with high-risk pregnancies. In the private sector, however, the incorporation of RSV prevention in the national immunization program will be crucial to making RSV vaccines and antibodies accessible and beneficial for all Indian infants—irrespective of birthplace. Article courtesy: Dr. Shreya Dubey - Consultant - Neonatology & Paediatrics, CK Birla Hospital, Gurugram Russia's Lavrov Sounds Alarm Over German Army Buildup Plan; 'Very Worrying, Need To…' One step to a healthier you—join Times Health+ Yoga and feel the change

FinTech push: Infosys opens GIFT City centre for BFSI digital services; new hub to house over 1,000 employees in hybrid model
FinTech push: Infosys opens GIFT City centre for BFSI digital services; new hub to house over 1,000 employees in hybrid model

Time of India

time18 minutes ago

  • Time of India

FinTech push: Infosys opens GIFT City centre for BFSI digital services; new hub to house over 1,000 employees in hybrid model

Infosys on Saturday announced the opening of its new development centre at Gujarat International Finance Tec-City (GIFT City) in Gandhinagar, marking a strategic expansion of its presence in India's premier international financial hub. Tired of too many ads? go ad free now The Bengaluru-based IT major said the facility will support more than 1,000 employees in a hybrid working setup and serve as a key TechFin hub delivering advanced digital solutions for global clients in the banking, financial services and insurance (BFSI) sector. 'This centre will offer a state-of-the-art facility for over 1,000 employees in a hybrid working model. It will function as a key TechFin hub, delivering advanced digital solutions for global BFSI clients,' Infosys said in a statement, as quoted an ET report. The centre will provide services in digital banking, capital markets, trade finance, regulatory and compliance functions, cards and payments, and risk management. It will also harness technologies such as AI, generative AI (GenAI), cloud, API, cybersecurity, and blockchain to enable cross-border digital solutions. According to the company, the GIFT City hub aligns with Infosys's global delivery strategy and strengthens its capabilities in delivering seamless tech-enabled financial services. 'Setting up our development centre in GIFT City is a strategic step aligned with our vision of leading innovation in financial services from within India's foremost international financial hub," said Jayesh Sanghrajka, chief financial officer, Infosys. Designed as a future-ready hybrid workplace, the centre will also focus on enhancing productivity and fostering collaboration, the company said.

Doctors remove LED bulb of toy phone from infant's respiratory tract in Ahmedabad
Doctors remove LED bulb of toy phone from infant's respiratory tract in Ahmedabad

Indian Express

time19 minutes ago

  • Indian Express

Doctors remove LED bulb of toy phone from infant's respiratory tract in Ahmedabad

A nine-month-old Junagadh-based boy, who had accidentally swallowed an LED bulb attached to a toy phone, was successfully treated at Ahmedabad Civil Hospital and the object successfully retrieved from his body, said people familiar with the matter on Saturday. The child, identified as Mohammad, son of Tabassum and Juned Yusuf, a carpenter, had been coughing for the previous fortnight, following which he was taken to a pediatrician in Junagadh, said his parents. During an X-ray, the doctors found an object lodged in his respiratory tract. The doctors recommended the boy's parents, residents of Mangrol in Junagadh, to a private hospital in Rajkot but since the cost proved prohibitive, the parents took him to Ahmedabad Civil Hospital. The child was immediately admitted to the Pediatric Surgery Department of the civil hospital on June 3. Head of the Pediatric Surgery Department, Dr Rakesh Joshi, and Dr Nilesh from the Anesthesia department along with their team successfully conducted a bronchoscopy (medical procedure) and extracted the LED bulb from the right main trachea of the child. After the operation, the child's health has been improving, said a doctor familiar with the development. The child is now healthy without any other problems, so he will be discharged from the hospital soon, said the doctor.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store